List view / Grid view
Included in this ebook are articles on how to develop more effective CAR T cells by modifying the CAR design and why recent findings about ferroptosis in cancer cells could enhance immunotherapies.
Scientists have developed a genetic screening platform to identify genes that can enhance immune cells to make them more persistent and increase their ability to eradicate tumour cells.
Researchers have developed a pH-sensitive drug delivery system in T cells using C-terminal dendrimers with Phenylalanine.
Pre-clinical research has found that CAR T cells can suppress gastrointestinal cancer cells without causing harm to healthy tissues.
Researchers have created an implantable biotechnology that produces and releases CAR T cells for attacking cancerous tumours.
Research in mice has shown that adding anti-inflammatory medication to immunotherapy and standard chemotherapy drugs may provide long-term suppression of aggressive bladder tumour growth.
Scientists have discovered a new strategy that can make pancreatic tumours visible to the immune systems of mice and vulnerable to immune attack.
Scientists have created a pipeline for identifying, prioritising and evaluating potential tumour antigens for personalised cancer vaccines.
Scientists have discovered the essential role of a ligand-dependent corepressor to potentially enable cancer cells to present tumour antigens on their surfaces.
New research has discovered metabolic mechanisms that contribute to how ovarian cancer escapes from immune attack and how combination therapies can exploit these pathways to improve ovarian cancer treatment.
A new study has highlighted an enzyme called ART1 as a promising target for immunity-boosting cancer treatments.
A new study has highlighted that gene expression profiling could enable rapid identification of anti-tumour immune cells for personalised immunotherapy.
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
An imaging technique identified emerging drugs that activate the STING protein to alter metabolic pathway activity in cancer cells.
Targeting stem-like T cells within certain lymph nodes could improve the number of cancer patients that respond to immunotherapy treatments.
